Empty vaccine promise
Passively allowing pandemic to run its course without accelerating roll-out is unacceptable
SOUTH Africa has the highest number of Covid-19 cases on the African continent.
It has more than 50 000 reported deaths. This may be an underestimate, looking at excess death statistics. The economic cost of the pandemic is evident on the streets and health-care facilities have been under considerable strain during the waves of the pandemic.
It was with much relief, elation and a renewed sense of hope that many healthcare workers enrolled in the Johnson and Johnson (J&J) vaccination trial in mid-February and received their much-anticipated jabs.
But the relief and elation has given way to frustration and disillusionment. The country’s roll-out is proceeding at a pace much slower than expected.
So far just over 293 000 South Africans have received their jab, which represents only a fraction of the 1.25million health-care workers who are first in line. This adds up to about 0.5% of the general population. The initial target of having 67% of the population vaccinated by the end of they year is now unlikely to be achieved.
The new roll-out plan promises to vaccinate 1.5 million by the end of the next month. Phase 2 is scheduled for May to October, and aims to vaccinate an additional 13 million people.
Several factors have contributed to South Africa’s halting start. These include global health inequality, South Africa’s delay in joining the global race for procurement, delays in the roll-out plan as well as uncertainty around efficacy and side effects of vaccines that were procured. At the current vaccination pace, it will take over a decade for South Africa to achieve herd immunity, with many lives lost along the way.
The biggest challenge has been access. Like other developing countries, South Africa has struggled to get doses. World Health Organization director Tedros Adhanom Ghebreyesus, put it succinctly: “Even as they speak the language of equitable access, some countries and companies continue to prioritise bilateral deals … driving up prices and attempting to jump to the front of the queue. This is wrong.”
An additional factor was South Africa’s slow start. The government was criticised for not actively engaging in vaccine procurement through other avenues at an earlier stage. By mid-January, the country’s participation in the Covax vaccine scheme only secured enough doses for about 10% of the population. On top of this, there has been a series of problems with the vaccines South Africa managed to secure. And the evolution of new variants and uncertainties around the efficacy of vaccines to emerging variants has slowed the country’s efforts.
The planned roll-out of the Oxford University-AstraZeneca vaccine from the Serum Institute of India was abruptly halted when local data showed decreased efficacy against the B.1.351 variant first identified in the country.
Then the J&J roll-out hit a roadblock, following the FDA-mandated suspension of its use in the US. The halt spoke to safety concerns and allowed the SA Health Products Regulatory Authority to evaluate the scientific evidence and establish appropriate risk to benefit ratios. Last week, it was announced that the J&J roll-out would be allowed to resume.
Another big issue that is likely to slow the momentum of the country’s vaccination programme is vaccine mistrust. In a survey done by the University of Johannesburg, up to a third of South Africans said that they would refuse a Covid-19 jab.
This could be echoing a deterioration in trust in the handling of the pandemic as a whole.
Misinformation, exaggeration and de-contextualisation of facts on various social media platforms have led to a large degree of vaccine mistrust among people. Balancing efficacy, safety, storage requirements and sustainability when it comes to vaccine selection is no easy task, but some countries have managed it better than others. South Africa is one of the countries that is lagging far behind.
The human and economic cost of passively allowing the pandemic to run its course in an era where vaccines are available is unacceptable. In addition, the emergence of variants is a compelling reason to step up vaccination efforts. Suboptimal levels of immunity will mean more people get ill and die. It will also increase the likelihood of new variants emerging.
The government needs to shift gear on a number of fronts. It needs to make vaccine procurement a budget priority and procure more vaccines.
Secondly, it needs to clarify urgently what the requirements are for the involvement of private medical providers in the vaccine roll-out.
It needs to expand the number of platforms (such as local clinics, GP practices, pharmacies, and private and state facilities) on which the vaccines are rolled out. If ever there was a need for public-private collaboration it is now – both in terms of funding vaccines and in providing platforms. This would enable large-scale vaccination to occur at the pace needed to turn the tide against Covid-19 in South Africa.
The government also needs to do more to raise public awareness and dispel myths at a community level.
Clearly, this will have to be a collaborative effort between all stakeholders from global efforts for equity to engagement by the pharmaceutical industry, procurement by government, involvement of private sector and widespread education of the publick=.